USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Non-small cell lung cancer (NSCLC) is often driven by epidermal growth factor receptor (EGFR) mutations.
• EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are effective but face challenges like resistance and limited response duration.
• Mechanisms such as EGFR amplification contribute to therapeutic limitations in NSCLC.

Discussion:

• This study investigates the USP21-EGFR-Lyn axis, revealing USP21 as a critical regulator of EGFR and Lyn stability in NSCLC.
• USP21 overexpression correlates with poor prognosis in NSCLC patients, as indicated by Gene Set Enrichment Analysis (GSEA).
• USP21 interacts with EGFR and Lyn, inhibiting their ubiquitination and degradation, thus maintaining oncogenic signaling pathways.

Key Insights:

• USP21 knockout lung cancer cell lines exhibit reduced proliferation, migration, colony formation, and tumor spheroid growth.
• USP21 depletion significantly suppressed tumor growth in vivo xenograft models.
• Pharmacological inhibition of USP21 with BAY-805 reduced EGF-induced tumor spheroid formation, demonstrating therapeutic potential.

Outlook:

• USP21 emerges as a promising therapeutic target for NSCLC treatment.
• Targeting USP21 may offer a complementary strategy to enhance existing EGFR-targeted therapies.
• Further research into the USP21-EGFR-Lyn axis could lead to novel treatment modalities for NSCLC.